Abstract: The disclosure provides systems and methods for data analysis of experimental data. The analysis can include reference data that are not directly generated from the present experiment, which reference data may be values of the experimental parameters that were either provided by a user, computed by the system with input from a user, or computed by the system without using any input from a user. Another example of such reference data may be information about the instrument, such as the calibration method of the instrument.

Abstract: Adjustable mattress assemblies are described in which a mattress incorporates regions where additional pressure reduction is adjustable via pliable fluid bladders filled with a gas or fluid. Such areas of the mattress where additional pressure reduction is desired may include regions of the mattress which support areas of the body which may be particularly susceptible to pressure ulcers such as the heels, sacral regions, etc.

Abstract: A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9?, Y10, Y10?, Y11, Y11?, Y12, Y12?, and Y13 are selected from the group consisting of hydrogen or deuterium, wherein at least one of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9?, Y10, Y10?, Y11, Y11?, Y12, Y12?, and Y13 is deuterium; and wherein each carbon is independently optionally replaced with 13C is disclosed herein. Pharmaceutical compositions comprising the compounds of Formula (I) and the use of the compounds as inhibitors of the enzyme poly ADP ribose polymerase (PARP) for the treatment of patients with BRCA-mutation positive ovarian cancer and BRCA-positive breast cancer is also disclosed herein.

Abstract: A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9?, Y10, Y10?, Y11, Y11?, Y12, Y12?, and Y13 are selected from the group consisting of hydrogen or deuterium, wherein at least one of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y9?, Y10, Y10?, Y11, Y11?, Y12, Y12?, and Y13 is deuterium; and wherein each carbon is independently optionally replaced with 13C is disclosed herein. Pharmaceutical compositions comprising the compounds of Formula (I) and the use of the compounds as inhibitors of the enzyme poly ADP ribose polymerase (PARP) for the treatment of patients with BRCA-mutation positive ovarian cancer and BRCA-positive breast cancer is also disclosed herein.

Abstract: The present invention provides the preparation and use of halophosphine-transition metal complex as catalysts for cross-coupling reaction to produce substituted aromatic heterocycles, biaryls and arylamines by reacting pyridyl halides or aryl halides with arylboronic acids or amines.

Abstract: The present invention provides the preparation and use of halophosphine-transition metal complex as catalysts for cross-coupling reaction to produce substituted aromatic heterocycles, biaryls and arylamines by reacting pyridyl halides or aryl halides with arylboronic acids or amines.

Abstract: Phosphine oxide and sulfoxide compounds were used with transition metals, preferably palladium and nickel, to produce biaryls, arylthiols, arylphosphine oxides and arylamines via cross-coupling reactions with aryl halides and arylboronic acids, aryl Grignard reagents, thiols, phosphine oxides or amines.

Abstract: The invention relates to the combinatorial approaches to the preparation of novel polymer-supported heteroatom bidentate (PN, PO, PS) ligand libraries and the corresponding free compounds after cleavage from the supports. These compounds are useful as novel ligands in the preparation of metal-containing catalysts.

Abstract: Novel phosphine and phosphine oxide ligands are prepared using polymeric supports. These compounds can be easily cleaved from the support, and along with the corresponding supported compounds, used as ligands in the preparation of novel, metal-complexed catalysts. The ligands are obtained by combinatorial synthesis. A process for preparing coumarin by contacting salicylaldehyde with an acrylate is also provided.

Abstract: Phosphine oxide and sulfoxide compounds were used with transition metals, preferably palladium and nickel, to produce biaryls, arylthiols, arylphosphine oxides and arylamines via cross-coupling reactions with aryl halides and arylboronic acids, aryl Grignard reagents, thiols, phosphine oxides or amines.

Abstract: The invention relates to the combinatorial approaches to the preparation of novel polymer-supported heteroatom bidentate (PN, PO, PS) ligand libraries and the corresponding free compounds after cleavage from the supports. These compounds are useful as novel ligands in the preparation of metal-containing catalysts.

Abstract: Phosphine oxide compounds were used with transition metals, preferably palladium, to produce biaryls and arylamines via cross-coupling reactions with aryl halides and arylboronic acids or amines.